Matsukawa A, Litterio G, Cormio A, Miszczyk M, Kardoust Parizi M, Fazekas T
Cancers (Basel). 2025; 17(2).
PMID: 39857987
PMC: 11763793.
DOI: 10.3390/cancers17020205.
Ishii K, Iguchi K, Matsuda C, Hirokawa Y, Sugimura Y, Watanabe M
J Clin Med. 2025; 13(24.
PMID: 39768760
PMC: 11678552.
DOI: 10.3390/jcm13247837.
Khorasanchi A, Jatwani K, Meng L, Collier K, Sundi D, Dason S
Cancers (Basel). 2025; 16(24).
PMID: 39766027
PMC: 11674059.
DOI: 10.3390/cancers16244127.
Beatson E, Risdon E, Napoli G, Price D, Chau C, Figg W
Int J Mol Sci. 2024; 25(11).
PMID: 38892296
PMC: 11172770.
DOI: 10.3390/ijms25116111.
Matsukawa A, Rajwa P, Kawada T, Bekku K, Laukhtina E, Klemm J
Int J Clin Oncol. 2024; 29(6):716-725.
PMID: 38582807
PMC: 11129990.
DOI: 10.1007/s10147-024-02485-4.
PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling.
Yang T, Chi Y, Wang X, Xu C, Chen X, Liu Y
Cell Death Dis. 2024; 15(2):128.
PMID: 38341429
PMC: 10858970.
DOI: 10.1038/s41419-023-06362-2.
Emerging Immunotherapy Approaches for Treating Prostate Cancer.
Meng L, Yang Y, Mortazavi A, Zhang J
Int J Mol Sci. 2023; 24(18).
PMID: 37762648
PMC: 10531627.
DOI: 10.3390/ijms241814347.
Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC.
White 3rd R, Bannister M, Day A, Bergom H, Tan V, Hwang J
Front Oncol. 2023; 13:1210487.
PMID: 37456235
PMC: 10348659.
DOI: 10.3389/fonc.2023.1210487.
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Nyquist M, Coleman I, Lucas J, Li D, Hanratty B, Meade H
Cancer Res. 2023; 83(17):2938-2951.
PMID: 37352376
PMC: 10472100.
DOI: 10.1158/0008-5472.CAN-22-2613.
Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy.
Congregado Ruiz B, Belenchon I, Lendinez Cano G, Medina Lopez R
Biomedicines. 2023; 11(4).
PMID: 37189723
PMC: 10135790.
DOI: 10.3390/biomedicines11041105.
Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres.
Zarba M, Angel M, Losco F, Zarba J, Pupilli J, Chacon M
Ecancermedicalscience. 2023; 16:1480.
PMID: 36819799
PMC: 9934967.
DOI: 10.3332/ecancer.2022.1480.
Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancer.
Qian C, Yang Q, Freedland S, Di Vizio D, Ellis L, You S
Am J Clin Exp Urol. 2023; 10(6):397-407.
PMID: 36636695
PMC: 9831918.
Endocrine and paracrine characteristics of neuroendocrine prostate cancer.
Arman T, Nelson P
Front Endocrinol (Lausanne). 2022; 13:1012005.
PMID: 36440195
PMC: 9691667.
DOI: 10.3389/fendo.2022.1012005.
Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1.
Makino Y, Kamiyama Y, Brown J, Tanaka T, Murakami R, Teramoto Y
Commun Biol. 2022; 5(1):299.
PMID: 35365763
PMC: 8976065.
DOI: 10.1038/s42003-022-03227-w.
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
Gurioli G, Conteduca V, Brighi N, Scarpi E, Basso U, Fornarini G
BMC Med. 2022; 20(1):48.
PMID: 35101049
PMC: 8805338.
DOI: 10.1186/s12916-022-02244-0.
Roles of enhancer RNAs in sex hormone-dependent cancers.
Zhang L, Ye X, Luo J, Chen J, Zheng W, Wu M
J Cancer Res Clin Oncol. 2022; 148(2):293-307.
PMID: 35064362
DOI: 10.1007/s00432-021-03886-y.
Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T, Kallenbach J, Baniahmad A
Int J Mol Sci. 2021; 22(20).
PMID: 34681745
PMC: 8538152.
DOI: 10.3390/ijms222011088.
The classical and updated models of androgen receptor nucleocytoplasmic trafficking.
Cole R, Pascal L, Wang Z
Am J Clin Exp Urol. 2021; 9(4):287-291.
PMID: 34541027
PMC: 8446772.
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E
BJU Int. 2021; 129(4):423-433.
PMID: 34171173
PMC: 9291853.
DOI: 10.1111/bju.15507.
Current Advances on the Important Roles of Enhancer RNAs in Molecular Pathways of Cancer.
Wang R, Tang Q
Int J Mol Sci. 2021; 22(11).
PMID: 34073237
PMC: 8198447.
DOI: 10.3390/ijms22115640.
